Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Chronic fatigue syndrome and mouse virus – no association

Chronic fatigue syndrome and mouse virus – no association

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Leukemia, psoriasis drugs may treat vascular diseases

Leukemia, psoriasis drugs may treat vascular diseases

Researchers find mechanism of action for cancer-killing peptides

Researchers find mechanism of action for cancer-killing peptides

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Atmospheric chlorine-content linked to risk of childhood leukaemia

Atmospheric chlorine-content linked to risk of childhood leukaemia

Leukemia protein plays a role in Alzheimer's disease

Leukemia protein plays a role in Alzheimer's disease

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet's blinatumomab data to be presented at two upcoming medical meetings

New technique can detect minute traces of tumoral DNA in biological fluids

New technique can detect minute traces of tumoral DNA in biological fluids

New insights into bone diseases

New insights into bone diseases

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Study examines long-term GI complications in childhood cancer survivors

Study examines long-term GI complications in childhood cancer survivors

International team identifies key protein in development of drug-resistant leukemia

International team identifies key protein in development of drug-resistant leukemia

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

Scientists identify key protein behind drug-resistant leukemia

Scientists identify key protein behind drug-resistant leukemia

A new gene expression analysis technique on a single molecule sequencer

A new gene expression analysis technique on a single molecule sequencer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.